The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

British Journal of Haematology

Volumn 110, Issue 4, 2000, Pages 925-934

  Storey, Robert F ^a   Sanderson, Heather M ^a   White, Ann E ^a   May, Jane A ^a   Cameron, Kathryn E ^a   Heptinstall, Stan ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Anti platelet drug; Calcium; P2 receptors; Platelet activation; Platelet secretion

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; AR 69931MX; CALCIUM ION; DESULFATOHIRUDIN; N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO) 5' ADENYLIC ACID; PADGEM PROTEIN; PURINE P2 RECEPTOR; PURINE P2T RECEPTOR; PURINE P2T RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; SEROTONIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CELL GRANULE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; THROMBOCYTE AGGREGATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANALYSIS OF VARIANCE; ANNEXIN A5; ASPIRIN; BLOOD PLATELETS; CALCIUM; COLLAGEN; CYTOSOL; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; SEROTONIN; STIMULATION, CHEMICAL; THROMBOXANE A2;

EID: 0033760391     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02208.x     Document Type: Article

References (44)

1. Interaction of platelet activation and coagulation
2. Mechanisms of cellular activation by platelet microparticles
3. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate
4. Deficiency of (33P), 2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production: Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production
5. Mechanisms of platelet aggregation
6. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups
7. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets
8. 1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors
9. Platelet aggregation in whole blood determined using the Ultra-Flo 100 platelet counter
10. Purinergic receptors on blood platelets
11. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
12. The action of ticlopidine on human platelets: Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins
13. Signal transduction and intracellular regulatory processes in platelets
14. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
15. Adenosine diphosphate-induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate
16. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour
17. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood
18. Differential effects of three radiographic contrast media on platelet aggregation and degranulation: Implications for clinical practice?
19. FPL 66096: A novel, highly potent and selective antagonist at human platelet P(2T)-purinoceptors
20. A novel series of P(2T) purinoceptor antagonists: Definition of the role of ADP in arterial thrombosis
21. Pharmacological profile of the novel P(2T)-purinoceptor antagonist. FPL 67085 in vitro and in the anaesthetized rat in vivo
22. Antagonists of the platelet P(2T)receptor: A novel approach to antithrombotic therapy
23. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation
24. ADP can induce aggregation of human platelet via both P2Y1 and P(2T) receptors
25. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
26. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
27. α(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels
28. Functional characterization of platelet ADP receptors
29. Dependence of human platelet functional responses on divalent cations: Aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents
30. 1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation: Further evidence for a distinct P2 receptor responsible for adenylyl cyclase inhibition
31. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets
32. The control of platelet responsiveness by agents that influence cyclic AMP metabolism
33. Factors responsible for ADP-induced release reaction of human platelets
34. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: Its influence on glycoprotein IIb-IIIa complex function
35. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents
36. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients
37. Characterization of P2x1 purinoreceptors on rat platelets: Effect of clopidogrel
38. Role of P2Y1 purinoceptor in ADP-induced platelet activation
39. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: Implications for assay methodology and comparison of different antagonists
40. First clinical study of the novel platelet ADP receptor (P2T-) antagonist ARC69931MX, assessing safety, tolerability and activity in patients with acute coronary syndromes
41. P2x1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression
42. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR-1 activating peptide through the late activation of phosphoinositide 3-kinase
43. Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications
44. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells